Biochemical and Structural Properties of Entecavir-Resistant Hepatitis B Virus Polymerase with L180M/M204V Mutations-Reference-Cited by-同舟云学术

Biochemical and Structural Properties of Entecavir-Resistant Hepatitis B Virus Polymerase with L180M/M204V Mutations

Published:2021-07-26 Issue:16 Volume:95 Page:
ISSN:0022-538X
Container-title:Journal of Virology
language:en
Short-container-title:J Virol

Author:

Nakajima Shogo¹²³,Watashi Koichi¹²⁴⁵,Kato Takanobu¹,Muramatsu Masamichi¹,Wakita Takaji¹,Tamura Noriko⁶,Hattori Shin-ichiro⁷,Maeda Kenji⁷,Mitsuya Hiroaki⁷⁸,Yasutake Yoshiaki⁶⁹^ORCID,Toyoda Tetsuya³^ORCID

Affiliation:

1. Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan

2. Department of Applied Biological Science, Tokyo University of Science, Noda, Japan

3. Choju Medical Institute, Toyohashi, Japan

4. Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan

5. MIRAI, Japan Science and Technology Agency, Saitama, Japan

6. Bioproduction Research Institute, National Institute of Advanced Industrial Science and Technology, Sapporo, Japan

7. National Center for Global Health and Medicine Research Institute, Tokyo, Japan

8. Experimental Retrovirology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA

9. Computational Bio Big-Data Open Innovation Laboratory, National Institute of Advanced Industrial Science and Technology, Tokyo, Japan

Abstract

HBV infects 257 million people in the world, who suffer from elevated risks of liver cirrhosis and cancer. ETV is one of the most potent anti-HBV drugs, and ETV resistance mutations in HBV RT have been extensively studied.

Funder

MEXT | Japan Society for the Promotion of Science

National Center for Global Health and Medicine

Japan Agency for Medical Research and Development

Publisher

American Society for Microbiology

Subject

Virology,Insect Science,Immunology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/JVI.02401-20

Reference48 articles.

1. World Health Organization. 2017. Global hepatitis report. World Health Organization, Geneva, Switzerland. http://apps.who.int/iris/bitstream/handle/10665/255016/9789241565455-eng.pdf?sequence=1.

2. Towards an HBV cure: state-of-the-art and unresolved questions—report of the ANRS workshop on HBV cure

3. Perspectives and limitations for nucleo(t)side analogs in future HBV therapies

4. Present and future therapies of hepatitis B: From discovery to cure

5. Molecular Modeling and Biochemical Characterization Reveal the Mechanism of Hepatitis B Virus Polymerase Resistance to Lamivudine (3TC) and Emtricitabine (FTC)

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Deviated binding of anti-HBV nucleoside analog E-CFCP-TP to the reverse transcriptase active site attenuates the effect of drug-resistant mutations;Scientific Reports;2024-07-08

2. Correction for Nakajima et al., “Biochemical and Structural Properties of Entecavir-Resistant Hepatitis B Virus Polymerase with L180M/M204V Mutations”;Journal of Virology;2024-03-19

3. Global prevalence and molecular characteristics of three clades within hepatitis B virus subgenotype C2: Predominance of the C2(3) clade in South Korea;Frontiers in Microbiology;2023-03-09

4. Susceptibility of Drug Resistant Hepatitis B Virus Mutants to Besifovir;Biomedicines;2022-07-07

5. Identification and Characterization of Besifovir-Resistant Hepatitis B Virus Isolated from a Chronic Hepatitis B Patient;Biomedicines;2022-01-26